VEGFA and retinopathy of prematurity: Bevacizumab Eliminates the Angiogenic Threat of Retinopathy of Prematurity (BEAT-ROP) study and Ranibizumab versus Laser Therapy for the Treatment of Very Low Birthweight Infants with Retinopathy of Prematurity (RAINBOW) study had proven the role of anti-vascular endothelial growth factor in treating ROP, especially zone 1 and aggressive posterior ROP [5, 6].